🚀 Breaking Oncology News: NSCLC, Ovarian Cancer, PROTAC & New Approvals
Stay up to date with the latest breakthroughs in cancer research, drug approvals, and clinical trial updates. From next-generation lung cancer treatments to major acquisitions in oncology, this episode covers the key developments shaping the future of cancer care.
🔬 Key Updates in This Video:
🧬 Fosun Pharma’s Foritinib receives NMPA acceptance for ALK+ NSCLC, showing a 77% reduction in disease progression risk.
💊 Hansoh Pharma’s Ameile is now approved for Stage III NSCLC maintenance therapy, extending progression-free survival to 30.4 months vs. 3.8 months with placebo.
🦠 Kelun-Biotech’s TROP2 ADC becomes the first globally approved TROP2 antibody-drug conjugate for EGFR-mutant NSCLC.
🔹 AstraZeneca’s Imfinzi gets the green light in China for perioperative NSCLC, reducing recurrence risk by 32%.
🇨🇦 Health Canada approves Lazertinib + Rybrevant, a first-line chemotherapy-free regimen for EGFR-mutated NSCLC, cutting disease progression risk by 30%.
🔬 Arvinas & Pfizer’s Vepdegestrant makes history as the first PROTAC degrader to show clinical benefit in ER+ HER2- breast cancer.
🧪 NiKang Therapeutics completes first cohort dosing for NKT3964, a highly selective CDK2 degrader targeting cyclin E-driven cancers.
🎗️ AbbVie’s Elahere reduces ovarian cancer death risk by 32% vs. chemotherapy in the MIRASOL trial.
📊 Zentalis Pharmaceuticals reports positive data for azenosertib (WEE1 inhibitor), with a 34.9% response rate in platinum-resistant ovarian cancer.
🧫 Sutro Biopharma’s FRα-targeting ADC achieves a 32% response rate and 96% disease control rate in platinum-resistant ovarian cancer patients.
🩺 Korea’s colorectal cancer screening rate hits a record 74.4%, with colonoscopy uptake jumping from 56.5% to 66.4%.
💰 Sun Pharma acquires Checkpoint Therapeutics for $355 million, adding FDA-approved PD-L1 therapy UNLOXCYT to its oncology portfolio.
🔬 Labcorp expands oncology diagnostics with a $225 million acquisition of select BioReference Health assets, strengthening its cancer testing services.
Stay ahead in oncology research! Like, share, and subscribe for weekly updates. Visit www.lqventures.com or email us at info@lqventures.com for expert healthcare consulting. See you next time!
#OncologyNews #CancerResearch #LungCancer #BreastCancer #OvarianCancer #ColorectalCancer #PharmaUpdates #ClinicalTrials #MedicalBreakthroughs